Bristol-Myers Squibb (NYSE:BMY – Get Free Report) issued its earnings results on Friday. The biopharmaceutical company reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.67 by $0.40, RTT News reports. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The business had revenue of $12.20 billion for the quarter, compared to the consensus estimate of $11.54 billion. During the same quarter last year, the firm posted $1.75 EPS. The business’s revenue for the quarter was up 8.7% compared to the same quarter last year. Bristol-Myers Squibb updated its FY24 guidance to $0.60-0.90 EPS and its FY 2024 guidance to 0.600-0.900 EPS.
Bristol-Myers Squibb Price Performance
BMY stock traded up $5.13 during trading on Friday, hitting $50.40. The company had a trading volume of 36,625,950 shares, compared to its average volume of 15,918,454. The firm has a market capitalization of $102.17 billion, a price-to-earnings ratio of -15.75, a P/E/G ratio of 16.73 and a beta of 0.44. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99. The business has a 50 day moving average of $41.63 and a 200 day moving average of $46.83. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $63.41.
Bristol-Myers Squibb Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.76%. The ex-dividend date of this dividend is Friday, July 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.
Wall Street Analyst Weigh In
Get Our Latest Stock Report on Bristol-Myers Squibb
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Featured Stories
- Five stocks we like better than Bristol-Myers Squibb
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- What is the Dogs of the Dow Strategy? Overview and Examples
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- Basic Materials Stocks Investing
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.